Barr Pharmaceuticals (BRL) Receives Approval for Generic Aredia
More News related to BRL
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
More News related to PFE
- Paladin Reports Record Third Quarter 2009 Financial Results
- Pfizer Merger to Shut Down Six R&D Sites, Resulting in 2,000 Layoffs, an Industrial Info News Alert
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Former Pfizer Global R&D President John LaMattina Joins PureTech Ventures as Senior Partner; PureTech Announces Partner Promotions
- Monsanto (MON) Agrees to Acquire Pfizer's (PFE) Chesterfield Village Research Center for $435M
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Barr Pharmaceuticals, Inc. (NYSE: BRL) announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s (NYSE: PFE) Aredia (pamindronate disodium) Injection, 30mg/mL, 60mg/mL, and 90mg/mL. The Company plans to launch its product in the fourth quarter of calendar 2008. With this approval, Barr's U.S. generic injectable portfolio now totals eight products.
Barr's generic Aredia (pamindronate disodium) product will compete in a market that had total annual sales of approximately $21 million for the twelve months ended June 2008, based on IMS sales data.[SM]
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
